Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) COO Sells $121,511.74 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,422 shares of the firm’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $50.17, for a total value of $121,511.74. Following the sale, the chief operating officer now owns 272,044 shares in the company, valued at $13,648,447.48. This trade represents a 0.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Patrick John Finn also recently made the following trade(s):

• On Friday, January 3rd, Patrick John Finn sold 229 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total value of $10,440.11.
• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total value of $496,320.00.
• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The shares were sold at an average price of $44.60, for a total transaction of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total transaction of $111,422.36.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $49.52 on Thursday. The business’s 50 day moving average price is $48.00 and its 200 day moving average price is $46.38. The company has a market cap of $2.94 billion, a price-to-earnings ratio of -13.76 and a beta of 1.85. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90.

Analysts Set New Price Targets

TWST has been the subject of a number of research reports. TD Cowen reissued a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Leerink Partners boosted their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Wolfe Research assumed coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. Barclays dropped their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Finally, Robert W. Baird raised their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $51.90.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of TWST. Wilmington Savings Fund Society FSB acquired a new stake in Twist Bioscience during the third quarter worth about $34,000. Van ECK Associates Corp grew its stake in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after buying an additional 267 shares during the period. Signaturefd LLC increased its holdings in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares during the last quarter. Beaird Harris Wealth Management LLC purchased a new stake in shares of Twist Bioscience during the 3rd quarter valued at approximately $95,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.